Connect Biopharma Holdings Limited Defined Contribution Plan, Cost
Connect Biopharma Holdings Limited (CNTB) reported Defined Contribution Plan, Cost of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-31
- Connect Biopharma Holdings Limited defined contribution plan, cost for fiscal 2025 was $200.00K, a 100.00% increase from fiscal 2024.
- Connect Biopharma Holdings Limited defined contribution plan, cost for fiscal 2024 was $100.00K, a 50.00% decline from fiscal 2023.
- Connect Biopharma Holdings Limited defined contribution plan, cost for fiscal 2023 was $200.00K.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $100.00K 10-K · filed 2026-03-31 |
| 2023-12-31 | $200.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |